Survodutide vs Retatrutide
Survodutide vs Retatrutide: dual GLP-1 + glucagon vs triple GLP-1 + GIP + glucagon. Two Phase 3 glucagon-arm compounds, weighed on obesity and fatty-liver disease (MASH).
The verdict
Both put glucagon to work, just to different degrees. Survodutide (Boehringer Ingelheim) is a dual GLP-1 plus glucagon agonist in Phase 3, with a strong liver angle and FDA Breakthrough Therapy status for MASH. Retatrutide (Lilly) adds GIP for a triple mechanism and owns the biggest weight-loss numbers in the class. Neither is approved. If maximum trial weight loss is the metric, Retatrutide leads; Survodutide is the more interesting one for fatty-liver disease, where its data stands out. Both are investigational, so this is a which-to-watch, not a which-to-buy.
Survodutide is Boehringer Ingelheim's dual agonist (GLP-1 + glucagon), a competitor to Retatrutide. Stronger fat-burn signal than the GLP-1-only drugs because it activates glucagon, which boosts metabolic rate. Phase 2 data is promising. Once-weekly.
Retatrutide is the newest weight-loss compound in development at Eli Lilly. It's a stronger cousin of Tirzepatide (Mounjaro / Zepbound) and pulls bigger weight loss in trials, often 20%+ of body weight. One injection per week. Side effects are real, especially in the first few weeks.
Which one should you pick?
Pick Survodutide if users plateaued on glp-1-only drugs or people targeting >15% body weight loss.
Pick Retatrutide if people plateaued on tirzepatide or users targeting >15% body weight loss.
Still torn between Survodutide and Retatrutide?
The AI Coach reads both, asks about your goal and experience, and tells you which one actually fits — plus how to dose and stack it. Free.